Osaka, JAPAN, March 31, 2021: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Orifarm Group (“Orifarm”) for a total value of up to $670 million USD.
The portfolio includes approximately 130 over-the-counter (OTC) and prescription pharmaceutical products sold in Europe, and two manufacturing sites located in Denmark and Poland.
This divestment agreement was first announced in April 2020 (global press release).
Takeda Norway press release April 2020.
The divested portfolio includes OTC products and food supplements, plus select products within the Cardiovascular, Anti-inflammatory, Respiratory, and Endocrinology therapeutic areas, primarily sold in Norway, Denmark, Belgium, Poland, Finland, Sweden, the Baltics and Austria. The products, while addressing key patient needs in these countries, are outside of the business areas Takeda has chosen as core to its global long-term growth.
- Today’s announcement marks an important step in the process of simplifying Takeda’s portfolio and focusing on our efforts to bring life transforming medicines to patients with highly specialized or rare conditions. We trust that Orifarm is the right partner to continue to bring to patients the over 130 OTC and prescription medicines now transitioning. As some of our colleagues are now also transitioning to Orifarm I would like to thank them for many years of service, for their commitment to patients and for the important role they had in building Takeda, says Duarte Marchand, General Manager, Takeda Norway.
For more information see global press release on Takeda.com (2021)
Eli Synnøve Gjerde
Cell: +47 402 19 735
Email: [email protected]
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet.
Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.